TC BIOPHARM (HOLDINGS) PLC C/WTS 08/02/2027 (TO PUR ADS) News

TCBP Increasing Treatment Capacity With Expanded Manufacturing Process

Yahoo FinanceApr 2 08:30 ET

TCBP Announces Exercise of Series D Warrants For Cash

Yahoo FinanceMar 18 08:30 ET

TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial

Yahoo FinanceFeb 22 09:32 ET

TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show'

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing...

PR NewswireJan 29 08:30 ET

TC Biopharm (NASDAQ:TCBPW) Trading Up 35.8%

TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) shares were up 35.8% during trading on Monday . The company traded as high as $0.12 and last traded at $0.11. Approximately 22,505 shares changed

Defense WorldApr 11, 2023 02:53 ET

TC Biopharm (NASDAQ:TCBPW) Shares Down 9.8%

TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) shares were down 9.8% during mid-day trading on Friday . The stock traded as low as $0.11 and last traded at $0.11. Approximately 1,500 shares tr

Defense WorldMar 18, 2023 01:52 ET

TC Biopharm (NASDAQ:TCBPW) Stock Price Down 29.5%

TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating)'s stock price was down 29.5% during trading on Wednesday . The stock traded as low as $0.12 and last traded at $0.14. Approximately 15,304 shares

Financial News LiveFeb 24, 2023 16:03 ET

TC Biopharm (NASDAQ:TCBPW) Trading Down 29.5%

TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating)'s stock price traded down 29.5% during mid-day trading on Wednesday . The company traded as low as $0.12 and last traded at $0.14. 15,304 shares

Defense WorldFeb 23, 2023 02:22 ET

TC BioPharm Shares Halted On Circuit Breaker ; Stock Trading Lower During The Company's Shareholder Update Conference Call

Conference Call to be held on Tuesday, February 21st, 2023 at Noon ETEDINBURGH, Scotland, Feb. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDA

Benzinga Real-time NewsFeb 21, 2023 12:38 ET

TC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T Cell Therapies

PRNewswireFeb 21, 2023 08:32 ET

TC BioPharm Announces New Chair Of The Board, Arlene Morris

TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer,

Benzinga Real-time NewsFeb 14, 2023 08:43 ET

TC BioPharm to Reschedule Shareholder Update Call and Webcast

Conference Call to be held on Tuesday, February 21st, 2023 at Noon ET EDINBURGH, Scotland, Feb. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP)

PR NewswireFeb 13, 2023 16:21 ET

TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division

Will oversee expansion of U.S. FDA Clinical TrialsEDINBURGH, Scotland, Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical

PR NewswireJan 30, 2023 08:39 ET

TC BioPharm to Host Shareholder Update Call

PRNewswireJan 20, 2023 08:35 ET

TC BioPharm Receives Notice Of Non-compliance With NASDAQ's Listing Rule 5550(b)(1)

TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), has received written notification from the listing qualifications staff of the Nasdaq Stock Market, LLC ("Nasd

Benzinga Real-time NewsJan 19, 2023 08:37 ET

TC BioPharm Announces Strategic Collaboration To Advance Gamma Delta T Cells In Oncology

Endeavor to focus on expanding understanding of gamma-delta T cells in oncological settings EDINBURGH, Scotland, Jan. 17, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company

Benzinga Real-time NewsJan 17, 2023 08:37 ET

TC BioPharm Announces Closing of $7.35 Million Private Placement

PRNewswireNov 30, 2022 18:45 ET

TC BioPharm Announces $7.35 Million Private Placement

PRNewswireNov 28, 2022 08:05 ET

TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating Its Lead Compound, OmnImmune, In Patients With Acute Myeloid Leukemia

3 Patients Dosed in 5 Patient Safety CohortEDINBURGH, Scotland, Nov. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage

Benzinga Real-time NewsNov 22, 2022 08:14 ET

TC BioPharm Receives MHRA Approval For 18-Month Extrapolated Shelf-Life Of Allogeneic Cell Therapy Product, OmnImmune

EDINBURGH, Scotland, Sept. 13, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform

Benzinga Real-time NewsSep 13, 2022 09:34 ET